Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 294,088,480
  • Shares Outstanding, K 2,469,879
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 22,107 M
  • EBITDA $ 27,945 M
  • 60-Month Beta 0.26
  • Price/Sales 4.39
  • Price/Cash Flow 10.11
  • Price/Book 5.44

Options Overview Details

View History
  • Implied Volatility 32.28% (-0.69%)
  • Historical Volatility 20.29%
  • IV Percentile 71%
  • IV Rank 53.80%
  • IV High 41.39% on 04/22/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 4) 3.11 (2.61%)
  • Put/Call Vol Ratio 0.87
  • Today's Volume 26,899
  • Volume Avg (30-Day) 20,063
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 538,421
  • Open Int (30-Day) 518,110
  • Expected Range 115.96 to 122.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.01
  • Number of Estimates 6
  • High Estimate $1.55
  • Low Estimate $-1.63
  • Prior Year $2.22
  • Growth Rate Est. (year over year) -145.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.72 +5.63%
on 03/20/26
124.00 -3.98%
on 04/09/26
+3.20 (+2.76%)
since 03/17/26
3-Month
106.03 +12.30%
on 01/28/26
125.14 -4.85%
on 02/25/26
+10.24 (+9.41%)
since 01/16/26
52-Week
73.31 +62.42%
on 05/15/25
125.14 -4.85%
on 02/25/26
+41.07 (+52.65%)
since 04/17/25

Most Recent Stories

More News
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and clinically meaningful improvement in event-free survival...

MRK : 119.07 (+3.13%)
3 Reasons We Love Merck (MRK)

3 Reasons We Love Merck (MRK)

MRK : 119.07 (+3.13%)
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season

ENFLONSIA is the first and only RSV preventive option in the European Union for administration to infants without the need for weight-based dosing

MRK : 119.07 (+3.13%)
This Merck (MRK) Stock Bullish Diagonal Trade Targets a Price of $130 by June 18

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

MRK : 119.07 (+3.13%)
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

MHK : 108.83 (+6.54%)
MRK : 119.07 (+3.13%)
GILD : 137.64 (-0.66%)
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?

Revolution Medicines stock rallies on impressive daraxonrasib Phase 3 results. Here’s why RVMD shares may sustain the momentum moving forward.

MRK : 119.07 (+3.13%)
ABBV : 208.38 (-0.29%)
RVMD : 148.63 (-0.43%)
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Based on results from IDeate-Lung01 phase 2 trial, with support from IDeate-PanTumor01 phase 1/2 trial If approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd...

MRK : 119.07 (+3.13%)
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Based on results from IDeate-Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trial If approved, ifinatamab deruxtecan would be a first-in-class B7-H3...

MRK : 119.07 (+3.13%)
1 Momentum Stock on Our Buy List and 2 We Question

1 Momentum Stock on Our Buy List and 2 We Question

MRK : 119.07 (+3.13%)
SLB : 52.66 (+1.80%)
ALNT : 74.40 (+5.70%)
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051

Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer

AZN : 204.80 (+2.16%)
ZNTL : 4.64 (-7.57%)
MRK : 119.07 (+3.13%)
APRE : 1.0000 (+10.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 123.97
2nd Resistance Point 121.58
1st Resistance Point 120.33
Last Price 119.07
1st Support Level 116.69
2nd Support Level 114.30
3rd Support Level 113.05

See More

52-Week High 125.14
Last Price 119.07
Fibonacci 61.8% 105.34
Fibonacci 50% 99.22
Fibonacci 38.2% 93.11
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.